Karyopharm Announces Changes to Its Clinical Leadership Team
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Karyopharm Therapeutics (KPTI) Wild Ride Occurring as M&A Speculation Proved Wrong Amid Executive Departure - RBC
February 22, 2022 12:40 PM ESTRBC Capital analyst Brian Abrahams weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) amid the recent turbulence in the stock, including the 20% up move on Friday on the conference cancellation, which triggered M&A speculation, and today's 31% downdraft on the departure of CMO Dr. Jatin... More
Morgan Stanley Reiterates Equalweight Rating on Karyopharm Therapeutics (KPTI), 'lack of potential takeout news likely to disappoint'
February 22, 2022 10:33 AM ESTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $10.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI).
The analyst comments "CMO departure surprising, but lack of potential takeout news likely to disappoint. This morning, Karyopharm announced several changes to the clinical leadership team. Most notable, Jatin Shah, EVP and CMO for the past 5 years, is leaving to pursue other opportunities... More
